echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Alx oncology Co., Ltd. completed the financing of USD 105 million round C

    Alx oncology Co., Ltd. completed the financing of USD 105 million round C

    • Last Update: 2020-02-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Editor's note: since the interaction of CD47 between cancer cells and immune system has become clear, many pharmaceutical companies have started to use CD47 as a research and development target

    There is evidence that tumor cells often signal "don't eat me" to macrophages by increasing the expression of CD47 on the cell surface

    Today, Alex Oncology (formerly alexo therapeutics) announced the completion of a $105 million round C financing to support the phase 2 clinical development of its CD47 checkpoint inhibitor, alx148, in combination with other anticancer therapies for solid and blood cancers

    Previously, the company has completed $60 million of financing

    This round of financing is based on the latest phase 1 clinical trial data of alx148 combined with rituximab in the treatment of relapsed / refractory non-Hodgkin's lymphoma (NHL)

    In this trial, the combination therapy achieved an objective response rate (ORR) of 43% and a median progression free survival (PFS) of 7.3 months in NHL patients

    CD47 protein is a natural inhibitor of macrophage function in human body

    By increasing the expression of CD47 on the cell surface, healthy cells can be prevented from being damaged by the immune system

    Blocking the CD47 SIRP α pathway may enhance innate and adaptive immunity against cancer

    After modification, the fusion protein developed by alx company can bind CD47 with stronger affinity than natural SIRP α

    Its main candidate drug, alx148, is an intravenous fusion protein, which contains two SIRP α high affinity CD47 binding domains linked to the inactive Fc domain of human immunoglobulin (as shown in the figure below)

    Alx148 structure diagram (picture source: alx oncology official website) The Fc domain of alx148 was modified to be inactive to FC γ receptor, which greatly reduced the toxicity of CD47 inhibitor to blood

    Moreover, the molecular weight of ALX148 is half of that of the antibody, so it can achieve linear pharmacokinetics with about half of the dose of anti CD47 antibody, and reach the occupancy rate of CD47 target

    In the preclinical model, alx148 blocked CD47 through FC dependent and independent mechanisms, enhancing the activity of checkpoint inhibitors and anti-cancer targeted antibodies

    By linking innate and adaptive immunity, alx148 activates a variety of immune cells to fight against tumors

    At present, the company is also studying the treatment prospect of its CD47 checkpoint inhibitor combined with Herceptin and keytruda in solid tumor patients

    Schematic diagram of action mechanism of alx148 (picture source: Official Website of alx Oncology) The press release noted that while round C financing will support the operation of Alex oncology for some time, there are indications that the company plans to raise more funds from other investors

    Last month, the company appointed Peter Garc í a as its chief financial officer, and in a statement disclosed his previous experience in "leading the IPO process."

    reference material: [1] Corey Goodman marshals $105M mega-round for his CD47 upstart, looking to break new ground in PhII,Retrieved February 12,2020,from https://endpts.com/corey-goodman-marshals-105m-mega-round-for-his-cd47-upstart-looking-to-break-new-ground-in-phii/ [2] ALX Oncology Announces Closing of $105 Million Series C Financing, Retrieved February 12,2020,from https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.